全文获取类型
收费全文 | 34623篇 |
免费 | 1764篇 |
国内免费 | 179篇 |
专业分类
耳鼻咽喉 | 417篇 |
儿科学 | 660篇 |
妇产科学 | 320篇 |
基础医学 | 4548篇 |
口腔科学 | 953篇 |
临床医学 | 2385篇 |
内科学 | 8381篇 |
皮肤病学 | 550篇 |
神经病学 | 2786篇 |
特种医学 | 1394篇 |
外科学 | 5624篇 |
综合类 | 197篇 |
预防医学 | 1194篇 |
眼科学 | 491篇 |
药学 | 2946篇 |
中国医学 | 91篇 |
肿瘤学 | 3629篇 |
出版年
2023年 | 158篇 |
2021年 | 620篇 |
2020年 | 291篇 |
2019年 | 443篇 |
2018年 | 558篇 |
2017年 | 462篇 |
2016年 | 550篇 |
2015年 | 586篇 |
2014年 | 766篇 |
2013年 | 979篇 |
2012年 | 1460篇 |
2011年 | 1577篇 |
2010年 | 900篇 |
2009年 | 795篇 |
2008年 | 1413篇 |
2007年 | 1487篇 |
2006年 | 1514篇 |
2005年 | 1622篇 |
2004年 | 1547篇 |
2003年 | 1507篇 |
2002年 | 1558篇 |
2001年 | 1256篇 |
2000年 | 1385篇 |
1999年 | 1233篇 |
1998年 | 463篇 |
1997年 | 370篇 |
1996年 | 360篇 |
1995年 | 304篇 |
1994年 | 306篇 |
1993年 | 292篇 |
1992年 | 830篇 |
1991年 | 750篇 |
1990年 | 757篇 |
1989年 | 801篇 |
1988年 | 739篇 |
1987年 | 672篇 |
1986年 | 640篇 |
1985年 | 593篇 |
1984年 | 474篇 |
1983年 | 363篇 |
1982年 | 209篇 |
1981年 | 180篇 |
1980年 | 177篇 |
1979年 | 294篇 |
1978年 | 242篇 |
1977年 | 180篇 |
1974年 | 177篇 |
1973年 | 160篇 |
1971年 | 155篇 |
1969年 | 176篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
2.
3.
4.
5.
6.
Kosuke Yoshihara Takayuki Enomoto Daisuke Aoki Yoh Watanabe Junzo Kigawa Nobuhiro Takeshima Hyoe Inomata Kana Hattori Masahisa Jinushi Hitoshi Tsuda Toru Sugiyama 《Cancer science》2020,111(9):3350-3358
Whether germline (g) breast cancer susceptibility gene (BRCA) mutations are located within or outside the ovarian cancer cluster region (OCCR) (1380‐4062 bp for gBRCA1, and between 3249‐5681 bp and 6645‐7471 bp for gBRCA2) may influence risk variations for ovarian cancers. This ad hoc analysis of the CHARLOTTE epidemiological study in Japan assessed the distribution of gBRCA1/2 mutations in patients with newly diagnosed ovarian cancer, and investigated an association between gBRCA1/2 mutation locations and ovarian cancer risk. Differences in patient background and clinical characteristics in subgroups stratified by gBRCA1/2 mutation locations were also evaluated. We analyzed the data of 93 patients (14.7%) from the CHARLOTTE study who were positive for gBRCA1/2 mutations. After excluding 16 cases with L63X founder mutation, 28 (65.1%) of gBRCA1 mutations were within the OCCR. Of 30 gBRCA2 mutations, 15 (50.0%) were within the OCCR. Of 27 patients (one patient excluded for unknown family history) with gBRCA1 mutations located in the OCCR, 11 (40.7%) had a family history of ovarian cancer; the proportion of patients with a family history of ovarian cancer and gBRCA1 mutations outside the OCCR was lower (13.3%). Sixty percent of patients with gBRCA1 mutations outside the OCCR had a family history of breast cancer; the proportion of patients with a family history of breast cancer and gBRCA1 mutations within the OCCR was relatively lower (33.3%). Understanding the mutation locations may contribute to more accurate risk assessments of susceptible individuals and early detection of ovarian cancer among gBRCA mutation carriers. 相似文献
7.
Takahiro Ando Hidenori Kage Yoko Matsumoto Koichi Zokumasu Takuma Yotsumoto Keita Maemura Yosuke Amano Kousuke Watanabe Jun Nakajima Takahide Nagase Daiya Takai 《Cancer science》2020,111(1):200-208
Integrins are transmembrane proteins that mediate cell adhesion to the extracellular matrix. Integrin α11 (ITGA11) is not expressed in normal alveolar epithelial cells and is a known receptor for collagen. While integrin α11β1 overexpression in the tumor stroma has been associated with tumor growth and metastatic potential of non–small cell lung cancer (NSCLC), little is known about the role of ITGA11 in tumor cells. Thus, we examined the RNA expression of ITGA11 by quantitative RT‐PCR in 80 samples collected from NSCLC patients who had undergone surgical resection and analyzed the clinical outcomes. We found that high expression of ITGA11 was associated with lower recurrence‐free survival in all NSCLC patients (P = 0.043) and in stage I NSCLC patients (P = 0.049). These results were consistent with in silico analyses of the Cancer Genome Atlas database. We also analyzed cell proliferation, migration and invasion capacity in lung cancer cell lines after overexpression of ITGA11. Overexpression of ITGA11 in lung cancer cell lines had little effect on cell proliferation but resulted in increased migration and invasion capacity. Our findings suggest that ITGA11 plays a significant role in cancer migration and invasion, leading to higher recurrence. ITGA11 expression may be a predictor of poor prognosis in patients with surgically resected NSCLC. 相似文献
8.
Yoshiki Imamura Takahiro Shinozaki Akiko Okada‐Ogawa Noboru Noma Masahiro Shinoda Koichi Iwata Akihiko Wada Osamu Abe Kelun Wang Peter Svensson 《Journal of oral rehabilitation》2019,46(6):574-587
Burning mouth syndrome (BMS) is a chronic oro‐facial pain disorder of unknown cause. It is more common in peri‐ and post‐menopausal women, and sex hormone dysregulation is believed to be an important causative factor. Psychosocial events often trigger or exacerbate symptoms, and persons with BMS appear to be predisposed towards anxiety and depression. Atrophy of small nerve fibres in the tongue epithelium has been reported, and potential neuropathic mechanisms for BMS are now widely investigated. Historically, BMS was thought to comprise endocrinological, psychosocial and neuropathic components. Neuroprotective steroids and glial cell line–derived neurotrophic factor family ligands may have pivotal roles in the peripheral mechanisms associated with atrophy of small nerve fibres. Denervation of chorda tympani nerve fibres that innervate fungiform buds leads to alternative trigeminal innervation, which results in dysgeusia and burning pain when eating hot foods. With regard to the central mechanism of BMS, depletion of neuroprotective steroids alters the brain network–related mood and pain modulation. Peripheral mechanistic studies support the use of topical clonazepam and capsaicin for the management of BMS, and some evidence supports the use of cognitive behavioural therapy. Hormone replacement therapy may address the causes of BMS, although adverse effects prevent its use as a first‐line treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) may have important benefits, and well‐designed controlled studies are expected. Other treatment options to be investigated include brain stimulation and TSPO (translocator protein 18 kDa) ligands. 相似文献
9.
10.
Kayoko Minakata Masako Suzuki Hideki Nozawa Kunio Gonmori Kanako Watanabe Osamu Suzuki 《Forensic Toxicology》2006,24(2):83-87
Platinum (Pt) levels were determined in various tissues and body fluids obtained from a patient who died 181 days after cisplatin
overdosing. The symptoms of cisplatin overdose, however, might have almost disappeared by day 40, and the patient’s death
was ascribed to the recurrence of malignant lymphoma. Determination of Pt derived from cisplatin was performed by electrospray
ionization mass spectrometry (ESI-MS) using silver (Ag) as internal standard. Pt and Ag complexed with diethyldithiocarbamate
(DDC) in wetashed blood, and tissue solutions were extracted into isoamyl alcohol, and then acidified with oxalic acid. By
injecting an aliquot of the isoamyl alcohol layer into a mass spectrometer in the direct flow injection mode, the quantitation
was performed using the signals of Pt(DDC)3
+ and Ag(DDC)2
+ at m/z 639 and 403, respectively. The Pt levels ranged from 25ng/ml in blood to 2050ng/g wet weight in the liver of the patient,
indicating that Pt remained at high levels in tissues, even after a period as long as 181 days after cisplatin overdosing. 相似文献